0001209191-23-006373.txt : 20230202
0001209191-23-006373.hdr.sgml : 20230202
20230202181431
ACCESSION NUMBER: 0001209191-23-006373
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230131
FILED AS OF DATE: 20230202
DATE AS OF CHANGE: 20230202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BJERKHOLT ERIC
CENTRAL INDEX KEY: 0001197350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 23582761
MAIL ADDRESS:
STREET 1: 132 PURDURE AVENUE
CITY: KENGSINGTON
STATE: CA
ZIP: 94708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-31
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001197350
BJERKHOLT ERIC
C/O CHINOOK THERAPEUTICS, INC.
400 FAIRVIEW AVE. NO., 9TH FLOOR
SEATTLE
WA
98109
0
1
0
0
Chief Financial Officer
Common Stock
2023-01-31
4
M
0
7333
A
40180
D
Common Stock
2023-01-31
4
S
0
2891
24.6823
D
37289
D
Restricted Stock Unirt
2023-01-31
4
M
0
7333
0.00
D
Common Stock
7333
14667
D
Stock Option (Right to Buy)
25.27
2023-01-31
4
A
0
84000
0.00
A
2033-01-30
Common Stock
84000
84000
D
Restricted Stock Unit
2023-01-31
4
A
0
21000
0.00
A
Common Stock
21000
21000
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
The stock option vests as to 25% of the total shares on January 31, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2024, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2023-02-02